跳至主要內容
科學

強化術後恢復方案

Lawton Plastic Surgery採用JOURNAVX輔助術後恢復

Lawton Plastic Surgery 由畢業於耶魯大學、持牌整形外科專科醫生 Dr. Gary Lawton 領軍,將 JOURNAVX 納入其術後康復流程之中。此舉標誌著品牌於處理接受拉腹手術、隆胸手術、提升手術、縮胸手術、植入物修正手術、抽脂手術,以及媽媽再造綜合手術等整容手術病人時,於傳統止痛管理方式上,出現重大轉變。

JOURNAVX 是一類新型非鴉片類藥物中,首個獲批准的藥物。此藥物透過一種獨特的作用機制運作,選擇性靶向周邊神經系統中傳遞痛感的鈉離子通道,而非激活鴉片受體。

Dr. Lawton 已將此藥物,整合入其為手術量較大的病例,所制定的一套全面、多模式術後康復流程之中。早期臨床觀察顯示,病人術後舒適度極佳,所需的急救麻醉藥物,較以往預期為少,並展現出更順暢的早期康復過程,更快恢復至術後正常里程碑。

英文原文

Lawton Plastic Surgery, under the leadership of Yale-trained, board-certified plastic surgeon Dr. Gary Lawton, has incorporated JOURNAVX into its postoperative recovery protocols. This move marks a significant departure from traditional pain management approaches for patients undergoing cosmetic procedures such as tummy tucks, breast augmentations, lifts, reductions, implant revisions, liposuction, and combined mommy makeovers.

JOURNAVX represents the first approved medication in a novel non-opioid drug class. It operates through a distinct mechanism that selectively targets pain-signalling sodium channels in the peripheral nervous system rather than activating opioid receptors.

Dr. Lawton has integrated this medication into a comprehensive multimodal postoperative recovery protocol for his higher-volume surgical cases. Early clinical observations indicate that patients experience excellent postoperative comfort, require fewer rescue narcotic medications than historically expected, and demonstrate smoother early recovery with a more rapid return to normal postoperative milestones.

前往原文

強化術後恢復方案
來源
Trend Hunter
發布
2026-07-29
品類
Science
出處
benzinga

同品類其他訊號